Cryoprecipitate: an outmoded treatment?
| Autor: | Simon J. Stanworth, Lucy Yang, T. Baglin |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
biology business.industry Acquired hypofibrinogenaemia Hematology Factor XIII Fibrinogen medicine.disease Surgery Von Willebrand factor Cryoprecipitate biology.protein medicine Coagulopathy Congenital hypofibrinogenaemia In patient business Intensive care medicine medicine.drug |
| Zdroj: | Transfusion Medicine. 22:315-320 |
| ISSN: | 0958-7578 |
| DOI: | 10.1111/j.1365-3148.2012.01181.x |
| Popis: | Cryoprecipitate is an allogeneic blood product prepared from human plasma. It contains factors VIII, von Willebrand factor (vWF), fibrinogen, fibronectin and factor XIII. Its use was first described in the 1960s for treatment of patients with factor VIII deficiency. It has also been used to treat patients with congenital hypofibrinogenaemia. Now, the most common use of cryoprecipitate is fibrinogen replacement in patients with acquired hypofibrinogenaemia and bleeding. Despite almost 50 years of use, evidence of efficacy is limited. This review provides an overview of the history of cryoprecipitate use, the current debates on the use of this product and future developments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|